November 17, 2026
The Centers for Medicare & Medicaid Services (CMS) announced a final rule establishing a permanent framework for the Medicare Drug Price Negotiation Program, beginning with negotiated prices effective in 2029. The rule sets policies for future negotiations over the prices of certain high-cost medications.
By February 1, 2027, CMS will select up to 20 additional eligible drugs covered under Medicare Part D and/or payable under Part B for the program’s fourth negotiation cycle. The agency may also select previously negotiated drugs for renegotiation, as appropriate. The announcement establishes the framework for that cycle; it does not immediately reduce drug prices.
The rule also codifies requirements for Part D plans to include selected drugs on their formularies once their negotiated “maximum fair prices” take effect. Additionally, it limits the negotiated prices plans pay pharmacies and other dispensing entities to the maximum fair price plus applicable dispensing fees.